Pfizer wins a “breakthrough” title for ALK/ROS1 contender lorlatinib after hustling into PhIII
Last June at ASCO, Pfizer researchers were happy to discuss the positive human data they had plumbed for lorlatinib (PF-06463922), their “next-generation” ALK/ROS1 tyrosine kinase inhibitor. Hustling it into Phase II, Pfizer saw this program as a key part of its oncology story, which has played a major role in winning new respect for the pharma giant’s pipeline efforts.
Now the FDA is endorsing that sentiment, giving Pfizer its breakthrough drug designation for this drug — now in a pivotal trial — which could help further accelerate it along the pathway to a potential approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.